CELLphenomics’ and KYAN Therapeutics combined platforms provide best-in-class solutions to support the biopharma industry
CELLphenomics and KYAN Therapeutics announced their new partnership today. By combining KYAN’s technology platform, Optim.AI™ – which utilizes artificial intelligence to predict the effects of drug combinations and CELLphenomics‘ proprietary PD3D® technology, this partnership aims to offer an efficient approach Mehr






